Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Mar-Apr;34(2):175-82.
doi: 10.1093/alcalc/34.2.175.

Blockade of the acquisition of ethanol-induced conditioned place preference by N-methyl-D-aspartate receptor antagonists

Affiliations

Blockade of the acquisition of ethanol-induced conditioned place preference by N-methyl-D-aspartate receptor antagonists

G Biała et al. Alcohol Alcohol. 1999 Mar-Apr.

Abstract

We have examined the influence of two different N-methyl-D-aspartate (NMDA) receptor antagonists on acquisition of the reinforcing properties of ethanol measured in the conditioned place preference (CPP) paradigm in rats. After receiving 15 daily injections of ethanol (0.5 g/kg, i.p.) before the conditioning trials, rats acquired the preference to the compartment paired with ethanol injections during conditioning. Both dizocilpine (0.1 mg/kg, i.p.), a non-competitive antagonist of the NMDA receptor, and L-701,324 (5 mg/kg, per os), an antagonist acting at the strychnine-insensitive glycine site of NMDA receptor complex, when co-administered repeatedly with ethanol, prevented the acquisition of ethanol-induced CPP. Dizocilpine alone provoked the development of CPP, having some intrinsic rewarding properties. In contrast, L-701,324 alone did not affect the CPP. These results suggest that the rewarding properties of ethanol could be, at least in part, due to its action at the NMDA receptor complex. Additionally, we can speculate that NMDA receptor antagonists can be useful in the treatment of ethanol dependence. Glycine receptor antagonists having no abuse potential might have advantages in terms of safety compared to non-competitive NMDA receptor antagonists.

PubMed Disclaimer

LinkOut - more resources